title: Arterial occlusion revealed by CT angiography predicts NIH stroke score and acute outcomes after IV tPA treatment.
abstract: OBJECTIVE
  The relationship between location of occlusion and clinical outcome is poorly understood in patients receiving intravenous tissue-type plasminogen activator (IV tPA). We postulated that acute stroke patients receiving IV tPA with patent vasculature or occult arterial occlusion by CT angiography (CTA) would have better outcomes and decreased hemorrhagic risk.
  
  
  METHODS
  We identified 47 patients from our prospective stroke database who underwent CTA before treatment with IV tPA. Site of occlusion was categorized as M1 segment of the middle cerebral artery, M2 segment, multiple (either carotid, basilar, or both middle and anterior cerebral arteries), or absent (no occlusion proximal to M3). The effect of site of occlusion on National Institutes of Health Stroke Scale (NIHSS), early improvement (> or = 4-point improvement in NIHSS at 24 hours after treatment), intracranial hemorrhages, and modified Rankin scale (mRS) at 7 days was tested in a multivariate analysis.
  
  
  RESULTS
  The location of occlusion correlated with initial NIHSS for multiple, M1, M2 and absent occlusions (median NIHSS scores were 18, 18, 15, 10, respectively) (P < .02, rank sum). Following adjustment for initial NIHSS, age, and time to treatment, the absence of occlusion remained associated with early improvement (OR 5.0, 95% CI 1.1-23.3; P = .04) and independence at day 7 (mRS < or = 2) (OR 6.8, 95% CI 1.3-34.6; P = .02). Overall prevalence of symptomatic hemorrhages was 6.4%. Patients without occlusion had no hemorrhages (0% versus 23.3%; P < .04).
  
  
  CONCLUSIONS
  Among patients treated with tPA, those with patent vasculature or occult distal occlusion on CTA before treatment have lower NIHSS, better chances of early improvement and early independence with fewer hemorrhages.
authors.affiliation: Department of Neurology, Massachusetts General Hospital, CNY 149, Room 6403, Charlestown, MA 02129, USA. jsims@partners.org
authors.forename: John R
authors.initials: JR
authors.lastname: Sims
authors.forename: Guy
authors.initials: G
authors.lastname: Rordorf
authors.forename: Eric E
authors.initials: EE
authors.lastname: Smith
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Koroshetz
authors.forename: Michael H
authors.initials: MH
authors.lastname: Lev
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Buonanno
authors.forename: Lee H
authors.initials: LH
authors.lastname: Schwamm
mesh_terms: D000368:Aged; D000792:Angiography / Q000379:methods*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D002537:Intracranial Arteriosclerosis / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D011446:Prospective Studies; D012720:Severity of Illness Index; D020521:Stroke / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000209:etiology; D014057:Tomography, X-Ray Computed
chemical_list: D005343:Fibrinolytic Agents